2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Smac Mimetic LCL161: new trials by email Literature Review of Smac Mimetic LCL161 trials Research Report on Smac Mimetic LCL161
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis Laboratory Biomarker Analysis, Questionnaire Administration, Smac Mimetic LCL161 - Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis | Phase 2 | Completed | M.D. Anderson Cancer Center | 50 | 2014-12-18 | 2023-06-06 |
| SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma Cyclophosphamide, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Completed | Mayo Clinic | 25 | 2013-11-01 | 2019-09-10 |
Multiple Myeloma (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1)
M.D. Anderson Cancer Center (1) · Mayo Clinic (1)
United States (2)
Naveen Pemmaraju (1) · Peter Bergsagel (1)
P30CA015083 (1)